RA375 manufacturers
- RA375
-
- $53.00
-
2026-05-11
- CAS:2649154-57-2
- Purity: 99.56%
- Supply Ability: 10g
|
| Product Name: | RA375 | | Synonyms: | RA375;Acetamide, N-[(1S)-2-[(3E,5E)-3,5-bis[(4-nitrophenyl)methylene]-4-oxo-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]-2-chloro- | | CAS: | 2649154-57-2 | | MF: | C30H25ClN4O7 | | MW: | 589 | | EINECS: | | | Product Categories: | | | Mol File: | 2649154-57-2.mol |  |
| | RA375 Chemical Properties |
| Boiling point | 857.537±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.428±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | solubility | Acetonitrile: Slightly soluble: 0.1-1 mg/ml
DMSO: Sparingly soluble: 1-10 mg/ml | | pka | 12.718±0.46(predicted) | | form | Solid | | color | Light yellow to yellow |
| | RA375 Usage And Synthesis |
| Uses | RA375 is a RPN13 (26S proteasome regulatory subunit) inhibitor. RA375 activates UPR signaling, ROS production and apoptosis. RA375 exhibits ten-fold greater activity against cancer lines than RA190, reflecting its nitro ring substituents and the addition of a chloroacetamide warhead[1]. | | in vivo | RA375 (10 mg/kg, ip) inhibits proteasome function and reduces ovarian tumor burden in mice[1]. | Animal Model: | RA375 (10 mg/kg, ip) inhibits proteasome function and reduces ovarian tumor burden in mice[1]. | | Dosage: | 10 mg/kg. | | Administration: | IP for a 5 days on, 2 days off cycle for two weeks. | | Result: | Reduced ovarian tumor burden in mice. |
| Animal Model: | Female Balb/c mice[1]. | | Dosage: | 5, 10, 20, 40, 60, 100 mg/kg (Pharmacological Analysis). | | Administration: | IP single dose. | | Result: | The dose of 40 mg/kg on alternate days for two weeks produced no observable toxicities or weight loss. |
| | References | [1] Ravi K Anchoori, et al. Structure-function Analyses of Candidate Small Molecule RPN13 Inhibitors With Antitumor Properties. PLoS One. 2020 Jan 15;15(1):e0227727. DOI:10.1371/journal.pone.0227727 |
| | RA375 Preparation Products And Raw materials |
|